These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality. Yu L; Zhang J; Li Y Front Immunol; 2022; 13():871076. PubMed ID: 36311748 [TBL] [Abstract][Full Text] [Related]
4. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies? Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265 [TBL] [Abstract][Full Text] [Related]
5. Drugs in early clinical development for the treatment of osteosarcoma. Heymann MF; Brown HK; Heymann D Expert Opin Investig Drugs; 2016 Nov; 25(11):1265-1280. PubMed ID: 27633385 [TBL] [Abstract][Full Text] [Related]
6. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Koshkina N; Yang Y; Kleinerman ES Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242 [TBL] [Abstract][Full Text] [Related]
7. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies. Ying H; Li ZQ; Li MP; Liu WC Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683 [TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma. Yang H; Zhao L; Zhang Y; Li FF Cancer Med; 2021 Aug; 10(16):5696-5711. PubMed ID: 34258887 [TBL] [Abstract][Full Text] [Related]
10. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. Liu C; Wang M; Xu C; Li B; Chen J; Chen J; Wang Z J Immunol Res; 2021; 2021():8970173. PubMed ID: 34877360 [TBL] [Abstract][Full Text] [Related]
11. Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors. Helm A; Tinganelli W; Simoniello P; Kurosawa F; Fournier C; Shimokawa T; Durante M Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):594-602. PubMed ID: 32980497 [TBL] [Abstract][Full Text] [Related]
12. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. Huang G; Nishimoto K; Yang Y; Kleinerman ES Adv Exp Med Biol; 2014; 804():203-17. PubMed ID: 24924176 [TBL] [Abstract][Full Text] [Related]
13. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer. Liu R; Hu Y; Liu T; Wang Y BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489 [TBL] [Abstract][Full Text] [Related]
14. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. Wen Y; Tang F; Tu C; Hornicek F; Duan Z; Min L Cancer Lett; 2022 Oct; 547():215887. PubMed ID: 35995141 [TBL] [Abstract][Full Text] [Related]
15. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. Gordon N; Kleinerman ES J Aerosol Med Pulm Drug Deliv; 2010 Aug; 23(4):189-96. PubMed ID: 20528149 [TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases. Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407 [TBL] [Abstract][Full Text] [Related]
17. The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. Huang Q; Liang X; Ren T; Huang Y; Zhang H; Yu Y; Chen C; Wang W; Niu J; Lou J; Guo W Cell Oncol (Dordr); 2021 Jun; 44(3):525-539. PubMed ID: 33788151 [TBL] [Abstract][Full Text] [Related]
18. Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma. Yan P; Wang J; Yue B; Wang X Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189171. PubMed ID: 39127243 [TBL] [Abstract][Full Text] [Related]
19. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Guenther LM; Rowe RG; Acharya PT; Swenson DW; Meyer SC; Clinton CM; Guo D; Sridharan M; London WB; Grier HE; Ecklund K; Janeway KA Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29251406 [TBL] [Abstract][Full Text] [Related]
20. Advances on immunotherapy for osteosarcoma. Yu S; Yao X Mol Cancer; 2024 Sep; 23(1):192. PubMed ID: 39245737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]